0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 20, 2025 03:02 ET (08:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。